Related Experiment Video
Updated: Jan 24, 2026

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages
Published on: June 23, 2013
Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis
Chao Wang1, Jingzhao Li2, Boya Zhang2
1Department of Cardiology, Tianjin Nankai Hospital, No. 6 Changjiang Road, Nankai District, Tianjin, China. chaowangbnm@yeah.net.
Background:
Controversial results still existed on the clinical utility of bone marrow-derived cells (BMCs) for cardiomyopathy (CMP). This study aims to reveal the true power of this promising approach by synthesizing all the available data on this subject matter.
Methods:
Twenty studies including 1418 patients were identified from systematic search. Weighted mean differences for changes in left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), 6-min walk distance, and NYHA functional class were estimated with a random-effects model. Major adverse cardiovascular event (MACE), rehospitalization, all-cause mortality, and patients' quality of life were also calculated.
Results:
Compared with the control group, BMC therapy resulted in greater LVEF (3.72%, 95% CI 2.31 to 5.13, P < 0.0001), 6-min walk distance (53.16, 95% CI 25.17 to 81.10, P = 0.0002), NYHA functional class (- 0.48, 95% CI - 0.65 to - 0.31, P < 0.0001), and smaller LVESV (- 16.79, 95% CI - 27.21 to - 6.38, P = 0.002). BMC treatment significantly reduced the mortality rate and improved patients' quality of life. No significant difference was found between the BMCs and control group in LVEDV, MACE, and rehospitalization rate. However, the outcomes showed a clear trend in favor of the BMC group. Subgroup analysis showed that LVEF improved greater in a subgroup of intracoronary infusion, BMSC, or higher cell dose.
Conclusion:
The results of the current meta-analysis suggest that BMC treatment for CMP is safe and feasible. This therapy was associated with persistent improvements in LV function, LV remodeling, functional class, patients' survival, and quality of life. Intracoronary infusion of high-dose (> 108) BMSC might be a better therapeutic option for CMP patients. Further evidences are needed to verify our results.
Insights
Bone marrow-derived cells (BMCs) safely improve heart function and quality of life in cardiomyopathy patients. This meta-analysis confirms BMC therapy enhances left ventricular ejection fraction and reduces mortality, offering a promising treatment option.
Area of Science:
- Regenerative Medicine
- Cardiology
- Cell Therapy
Background:
- Clinical utility of bone marrow-derived cells (BMCs) for cardiomyopathy (CMP) remains controversial.
- Existing data requires synthesis to ascertain the efficacy of BMC therapy for CMP.
Purpose of the Study:
- To conduct a meta-analysis synthesizing available data on the clinical utility of BMCs for CMP.
- To evaluate the safety and effectiveness of BMC treatment in patients with cardiomyopathy.
Main Methods:
- Systematic search identified 20 studies with 1418 patients.
- Random-effects model used to estimate weighted mean differences for key clinical outcomes.
- Analysis included left ventricular ejection fraction (LVEF), volumes, functional capacity, and adverse events.
Main Results:
- BMC therapy significantly improved LVEF (3.72%), 6-min walk distance, and NYHA functional class, while reducing LVESV.
- Treatment also reduced mortality rates and improved quality of life.
- No significant differences in LVEDV, MACE, or rehospitalization, though trends favored BMCs. Intracoronary infusion, BMSC, and higher cell doses showed greater LVEF improvement.
Conclusions:
- BMC treatment for CMP is safe, feasible, and associated with persistent improvements in cardiac function, remodeling, and survival.
- Intracoronary infusion of high-dose bone marrow-stimulating cells (BMSC) may be a superior therapeutic strategy.
- Further research is warranted to validate these findings.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Survey Safety
Self-Efficacy

